Kaustav Banerjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaustav Banerjee has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Krishna Pada Bhabak
Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India
4 shared publications - Nikita Pal
Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India
2 shared publications - Shilpi Sarkar
Department Biosciences and Bioengineering Indian Institute of Technology Guwahati 781039 Guwahati, Assam India
2 shared publications - Tapas Kumar Mandal
Department of Chemical Engineering, Indian Institute of Technology Guwahati, Guwahati, India
2 shared publications - Abu Sufian
Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India
1 shared publication - Debojit Bhattacherjee
Department of Chemistry, Indian Institute of Technology Guwahati, Guwahati-781039, Assam, India
1 shared publication
Latest Publications
- 12 December 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 31 (11) , e202403026
Synthesis of Thiazolidinedione‐ and Triazole‐Linked Organoselenocyanates and Evaluation of Anticancer Activities Against Breast Cancer with Mechanistic Investigations
Organoselenocyanates are important classes of organoselenium compounds having potential pharmaceutical applications in cancer biology. In the present study, two different series of organoselenocyanates (15 a–15 c and 16 a–16 c) incorporating crucial heterocyclic pharmacophores such as 2,4‐thiazolidine‐1,3‐dione and 1,2,3‐triazole were rationally designed. The organoselenocyanates were synthesized using multi‐step organic synthesis and investigated for their anticancer activities against triple‐negative breast cancer cells. Based on the preliminary anti‐proliferative activities and the selectivity index towards cancer cells over the normal cells, 2,4‐thiazolidine‐1,3‐dione‐based selenocyanate 15 a was identified as the lead analogue for detailed investigations. In addition to the anti‐migratory activity, compound 15 a induced G1‐phase arrest of the cell cycle and led to early apoptosis. Further studies on the redox balance of MDA‐MB‐231 cells indicated the antioxidant nature of 15 a with the quenching of ROS level and upregulation of TrxR1 expression. Detailed mechanistic investigations with the expression levels of key‐cancer marker proteins revealed that the selenocyanate 15 a induced the activation of ERK pathway by upregulating p‐ERK expression with the subsequent downregulation of p‐Akt and c‐Myc levels leading to the inhibition of cellular proliferation. Therefore, the primary outcomes of the study would be valuable in the development of chemotherapeutic agents towards the treatment of triple‐negative breast cancer.
- 12 December 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 31 (11) , e202403026
Synthesis of Thiazolidinedione‐ and Triazole‐Linked Organoselenocyanates and Evaluation of Anticancer Activities Against Breast Cancer with Mechanistic Investigations
Organoselenocyanates are important classes of organoselenium compounds having potential pharmaceutical applications in cancer biology. In the present study, two different series of organoselenocyanates (15 a–15 c and 16 a–16 c) incorporating crucial heterocyclic pharmacophores such as 2,4‐thiazolidine‐1,3‐dione and 1,2,3‐triazole were rationally designed. The organoselenocyanates were synthesized using multi‐step organic synthesis and investigated for their anticancer activities against triple‐negative breast cancer cells. Based on the preliminary anti‐proliferative activities and the selectivity index towards cancer cells over the normal cells, 2,4‐thiazolidine‐1,3‐dione‐based selenocyanate 15 a was identified as the lead analogue for detailed investigations. In addition to the anti‐migratory activity, compound 15 a induced G1‐phase arrest of the cell cycle and led to early apoptosis. Further studies on the redox balance of MDA‐MB‐231 cells indicated the antioxidant nature of 15 a with the quenching of ROS level and upregulation of TrxR1 expression. Detailed mechanistic investigations with the expression levels of key‐cancer marker proteins revealed that the selenocyanate 15 a induced the activation of ERK pathway by upregulating p‐ERK expression with the subsequent downregulation of p‐Akt and c‐Myc levels leading to the inhibition of cellular proliferation. Therefore, the primary outcomes of the study would be valuable in the development of chemotherapeutic agents towards the treatment of triple‐negative breast cancer.
- 21 November 2024
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 28 (7)
Structurally Innovative Benzimidazole‐fused Ionic Organoselenium Compounds: Prevalence of Se⋅⋅⋅N/Se Chalcogen Bonds with the Selenocyanate Receptor
The non‐covalent interactions in molecules play important roles towards their applications in various aspects such as molecular recognition, catalysis, supramolecular chemistry, structural biology, pharmacology etc. Interestingly, among various non‐bonding interactions, chalcogen bonding (ChB) has been extensively studied in different facets of crystal engineering over the last several years. The present study demonstrates the presence of Se⋅⋅⋅N or Se⋅⋅⋅Se ChB in the benzimidazole‐fused cyclic selenazonium selenocyanates (6–8), cyclic selenazinium selenocyanates (9–10) and the acyclic benzimidazolium analogs having two different types of selenocyanate units (11–12). The final organoselenium compounds were synthesized from benzimidazole in several steps in reasonably good yields. The single‐crystal X‐ray structures of the compounds revealed that both the N atom and Se atom of the negatively charged SeCN unit act as ChB acceptors in building the Se⋅⋅⋅N or Se⋅⋅⋅Se ChB interactions along with the additional hydrogen bonding (HB) interactions. Moreover, the structural optimization and natural bond orbital (NBO) analyses were carried out using density functional theory (DFT) to calculate the natural charges on different Se centers and the strength of second‐order perturbation energy (E2) for the ChB interactions. Finally, surface electrostatic potential (SEP) of the compounds was developed to visualize the formation of σ‐holes.
- 21 November 2024
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 28 (7)
Structurally Innovative Benzimidazole‐fused Ionic Organoselenium Compounds: Prevalence of Se⋅⋅⋅N/Se Chalcogen Bonds with the Selenocyanate Receptor
The non‐covalent interactions in molecules play important roles towards their applications in various aspects such as molecular recognition, catalysis, supramolecular chemistry, structural biology, pharmacology etc. Interestingly, among various non‐bonding interactions, chalcogen bonding (ChB) has been extensively studied in different facets of crystal engineering over the last several years. The present study demonstrates the presence of Se⋅⋅⋅N or Se⋅⋅⋅Se ChB in the benzimidazole‐fused cyclic selenazonium selenocyanates (6–8), cyclic selenazinium selenocyanates (9–10) and the acyclic benzimidazolium analogs having two different types of selenocyanate units (11–12). The final organoselenium compounds were synthesized from benzimidazole in several steps in reasonably good yields. The single‐crystal X‐ray structures of the compounds revealed that both the N atom and Se atom of the negatively charged SeCN unit act as ChB acceptors in building the Se⋅⋅⋅N or Se⋅⋅⋅Se ChB interactions along with the additional hydrogen bonding (HB) interactions. Moreover, the structural optimization and natural bond orbital (NBO) analyses were carried out using density functional theory (DFT) to calculate the natural charges on different Se centers and the strength of second‐order perturbation energy (E2) for the ChB interactions. Finally, surface electrostatic potential (SEP) of the compounds was developed to visualize the formation of σ‐holes.
- 11 May 2022
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 46 (24) , 11910-11926
Benzimidazole-based ionic and non-ionic organoselenium compounds: innovative synthetic strategies, structural characterization and preliminary anti-proliferative activities
The design of and synthetic routes to three different classes of structurally innovative ionic (7a and 7b, 8a–8c and 9a–9c) and non-ionic organoselenium compounds (10a–10c) containing benzimidazole pharmacophores and substituted phenyl rings (4-H, 4-NO2 and 4-OMe) are described. The ionic sets of compounds consisted of benzimidazole-fused cyclic selenazolium selenocyanates (7a and 7b), selenazinium selenocyanates (8a–8c) and acyclic benzimidazolium selenocyanates (9a–9c). The final compounds could be synthesized effectively from the suitable benzimidazole derivatives in multi-step synthesis and the selenium incorporation was done using potassium selenocyanate. All the purified compounds were characterized by analytical methods and the structure of a representative selenazolium selenocyanate (7b) was further confirmed by single-crystal X-ray diffraction study. A mechanistic outline was proposed for the cyclized products. Considering the hints about the anti-cancer and chemopreventive activities of reported organoselenocyanates, the innovative sets of synthesized ionic and non-ionic compounds were evaluated for their preliminary anti-proliferative activities against highly aggressive triple-negative breast cancer (MDA-MB-231, human breast adenocarcinoma) cells. Interestingly, our in vitro studies revealed the highly enhanced anti-proliferative activities of non-ionic organoselenocyanates over ionic organoselenium compounds in general and the significantly high selectivity of the lead compound 10c having the 4-NO2 group towards cancer cells over normal cells. The lead compound exhibited potent anti-migratory activity, induced dose-dependent cell cycle arrest in the G1 phase and modulated the expression levels of key cancer-marker proteins. Our results reveal that 10c exhibits anti-proliferative activity most likely by arresting cells in the G1 phase and by enhancing intracellular ROS levels in triple-negative breast cancer cells.
- 11 May 2022
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 46 (24) , 11910-11926
Benzimidazole-based ionic and non-ionic organoselenium compounds: innovative synthetic strategies, structural characterization and preliminary anti-proliferative activities
The design of and synthetic routes to three different classes of structurally innovative ionic (7a and 7b, 8a–8c and 9a–9c) and non-ionic organoselenium compounds (10a–10c) containing benzimidazole pharmacophores and substituted phenyl rings (4-H, 4-NO2 and 4-OMe) are described. The ionic sets of compounds consisted of benzimidazole-fused cyclic selenazolium selenocyanates (7a and 7b), selenazinium selenocyanates (8a–8c) and acyclic benzimidazolium selenocyanates (9a–9c). The final compounds could be synthesized effectively from the suitable benzimidazole derivatives in multi-step synthesis and the selenium incorporation was done using potassium selenocyanate. All the purified compounds were characterized by analytical methods and the structure of a representative selenazolium selenocyanate (7b) was further confirmed by single-crystal X-ray diffraction study. A mechanistic outline was proposed for the cyclized products. Considering the hints about the anti-cancer and chemopreventive activities of reported organoselenocyanates, the innovative sets of synthesized ionic and non-ionic compounds were evaluated for their preliminary anti-proliferative activities against highly aggressive triple-negative breast cancer (MDA-MB-231, human breast adenocarcinoma) cells. Interestingly, our in vitro studies revealed the highly enhanced anti-proliferative activities of non-ionic organoselenocyanates over ionic organoselenium compounds in general and the significantly high selectivity of the lead compound 10c having the 4-NO2 group towards cancer cells over normal cells. The lead compound exhibited potent anti-migratory activity, induced dose-dependent cell cycle arrest in the G1 phase and modulated the expression levels of key cancer-marker proteins. Our results reveal that 10c exhibits anti-proliferative activity most likely by arresting cells in the G1 phase and by enhancing intracellular ROS levels in triple-negative breast cancer cells.